Medpage Today on MSN6d
Hitting Psoriatic Arthritis Early With Apremilast Helps Some Patients, Trial FindsMore patients with oligoarticular psoriatic arthritis (PsA) saw symptoms largely disappear when apremilast (Otezla) was ...
USA: The results of the FOREMOST trial indicate that apremilast is effective for patients with early psoriatic arthritis (PsA ...
Westside Current on MSN18h
TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASEAmgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the ...
The biotech industry is poised for significant growth, fueled by advanced technologies, the increased commercialization of ...
Improvements in 2 patient-reported outcome measures were observed among patients with psoriasis treated with deucravacitinib vs placebo or apremilast.
The mucocutaneous and articular clinical phenotype is the most common presentation of Behçet’s disease (BD).1 Current ...
Amgen (NASDAQ: AMGN) today announced the presentation of new data across its broad oncology pipeline and portfolio at the ...
Amgen (NASDAQ:AMGN) today announced the presentation of new data showcasing IMDELLTRATM (tarlatamab-dlle), a first-in-class delta-like ligand 3 (DLL3)-targeting Bispecific T-cell Engager (BiTE®) ...
Amgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the treatment of active or high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback